HHS, Industry Partners Expand U.S.-Based Pharmaceutical Manufacturing for COVID-19 Response | HHS.gov

HHS, Industry Partners Expand U.S.-Based Pharmaceutical Manufacturing for COVID-19 Response | HHS.gov

HHS, Industry Partners Expand U.S.-Based Pharmaceutical Manufacturing for COVID-19 Response

HHS will work with a team of private partners led by Phlow Corporation of Richmond, VA, to expand pharma-ceutical manufacturing in the U.S. for use in producing medicines needed during the COVID-19 response and future public health emergencies. The Phlow-led team will provide U.S.-based capacity to produce the active pharmaceutical ingredients (APIs) and the chemical compounds for those ingredients to make critical medicines to help alleviate or prevent drug shortages.